UPDATE on Drug Applications to FDA

Jul 3, 2014, 17:09 PM
The FDA has accepted submissions for new drug applications (NDAs) from both InterMune, Inc. and Boehringer-Ingelheim.

"The submission and acceptance of the NDAs for pirfenidone and nintedanib by the Food and Drug Administration is an important step forward in the elevation of these potential therapies for patients with idiopathic pulmonary fibrosis," said Pulmonary Fibrosis Foundation Chief Medical Officer Gregory Cosgrove, MD. "The identification of a treatment and eventually a cure for pulmonary fibrosis is a key element of the mission of the PFF and a process we support through advocacy, education and funding research."

Visit the PFF Disease Education page for further information about living with PF, including access to the May 28 webinar, "Ask a Doc: Clinical Trial Update." Experts addressed data from Phase III trials and answered participant's questions. Register for July disease education webinars, scheduled for July 16 and July 23.

Call or email the PFF Patient Communication Center, 844.Talk. PFF and pcc@pulmonaryfibrosis.org, to let us know which symptoms and treatment approaches matter most to you and to request further information regarding PF.
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >